Evelo Biosciences identifies new lead oncology candidate

 

• In addition to positive topline data from early-stage atopic dermatitis study with EDP1815 announced earlier today, Evelo Biosciences (EVLO +12.2%) has announced that it is prioritizing EDP1908 as its lead clinical candidate in oncology given its superior preclinical activity over EDP1503.
• The Company said it will halt recruitment in Phase 1/2 trial of EDP1503 and will wind down the study. Additionally, interim data from Phase 1/2 trial evaluating EDP1503+pembrolizumab combination, in triple-negative breast cancer, showed that the combination was well-tolerated, with an overall response rate of 17% and a disease control rate of 25% in the 12 patients who received the higher dose. Data were presented at the San Antonio Breast Cancer Symposium.
• Plans to advance EDP1908 into the clinic in 1H of 2022.
• https://seekingalpha.com/news/3642989-evelo-biosciences-identifies-new-lead-oncology-candidate